GlassScriptPhysician profile
Donna M Kentley
NPI 1356495907
$2,491.31
in general payments reported to CMS, 2019-2025
36 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $295 · 2023: $601 · 2024: $769 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $285.47 | 2021-2023 | Pomalyst, Opdivo, Opdualag |
| Pfizer INC. | $217.23 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $197.91 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $195.81 | 2022-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $155.91 | 2022-2024 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $139.78 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $134.88 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $132.45 | 2024 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $85.77 | 2023-2025 | Fotivda |
| Eisai INC. | $79.81 | 2023-2025 | |
| Daiichi Sankyo INC. | $73.77 | 2024-2025 | Vanflyta, Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $66.30 | 2023-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $63.16 | 2023-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $60.09 | 2024-2025 | Enhertu, Tagrisso |
| Emd Serono, INC. | $57.90 | 2021-2024 | Bavencio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $56.72 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $52.04 | 2023-2024 | |
| Taiho Oncology, INC. | $40.77 | 2023 | |
| Genentech USA, INC. | $30.47 | 2021-2024 | Perjeta, Phesgo |
| Beigene USA, INC. | $30.41 | 2024 | Brukinsa |
| Fresenius Kabi USA, LLC | $28.76 | 2025 | |
| Invivyd INC | $28.53 | 2025 | Pemgarda |
| Regeneron Healthcare Solutions, INC. | $27.21 | 2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.37 | 2023 | Gilotrif |
| Seagen INC. | $25.76 | 2022 | |
| Abbvie INC. | $24.55 | 2022 | |
| Epizyme, INC. | $23.73 | 2021 | |
| Stemline Therapeutics INC. | $18.92 | 2025 | Elzonris |
| Geron Corporation | $18.38 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $18.23 | 2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $16.90 | 2024 | Fruzaqla |
| Spectrum Pharmaceuticals INC. | $16.83 | 2025 | Rolvedon |
| Adc Therapeutics America, INC. | $15.77 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.54 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.30 | 2024 | Monoferric |
| Amgen INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Kentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.